Gilead Sciences Files 8-K on Financials

Ticker: GILD · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-k, results-of-operations

Related Tickers: GILD

TL;DR

Gilead dropped an 8-K on Nov 6th with financial results. Check it out.

AI Summary

On November 6, 2024, Gilead Sciences, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 333 Lakeside Drive, Foster City, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Gilead Sciences' financial performance and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Gilead Sciences, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on November 6, 2024.

What is the principal executive office address for Gilead Sciences, Inc.?

The principal executive office address for Gilead Sciences, Inc. is 333 Lakeside Drive, Foster City, California, 94404.

What is the Commission File Number for Gilead Sciences, Inc.?

The Commission File Number for Gilead Sciences, Inc. is 0-19731.

What is the SIC code for Gilead Sciences, Inc.?

The Standard Industrial Classification (SIC) code for Gilead Sciences, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

From the Filing

0000882095-24-000025.txt : 20241106 0000882095-24-000025.hdr.sgml : 20241106 20241106160921 ACCESSION NUMBER: 0000882095-24-000025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 241430982 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20241106.htm FORM 8-K gild-20241106 0000882095 false 0000882095 2024-11-06 2024-11-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 6, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Section 2 - FINANCIAL INFORMATION Item 2.02      Results of Operations and Financial Condition. On November 6, 2024 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial

View on Read The Filing